Seoul, South Korea – Hanmi Pharmaceutical, a leading Korean pharmaceutical company, has announced the development of a groundbreaking new drug for the treatment of hypertension. The company has submitted a domestic regulatory application for "Amoxatant Plus L," a low-dose triple combination hypertension drug that is poised to become the "next Rosuvastatin."
Amoxatant Plus L is a unique combination of three antihypertensive agents, each with a distinct mechanism of action. This formulation, designed for patients in the early stages of hypertension, aims to provide a more effective and convenient treatment option.
"We are excited to introduce Amoxatant Plus L, which represents a significant advancement in the treatment of hypertension," said Kim Na-young, Executive Director of New Product Development at Hanmi Pharmaceutical. "As a low-dose triple combination, it has the potential to redefine the first-line treatment paradigm for hypertension."
The development of Amoxatant Plus L has garnered significant attention from the global medical community. Clinical trials have demonstrated the drug's efficacy and safety in treating hypertension, and the results were presented at the European Society of Hypertension (ESH) Congress.
"By simultaneously targeting multiple pathophysiological pathways, this new approach can potentially improve patient outcomes more effectively," said Lee Moo-yong, President of the Korean Society of Hypertension.
Hanmi Pharmaceutical has been at the forefront of hypertension treatment in Korea, with its Amoxatant family of drugs consistently ranking as the top-prescribed hypertension medication for six consecutive years. The company's commitment to research and development has led to a pipeline of innovative drugs, solidifying its position as a leader in the Korean pharmaceutical industry.
"We will continue to develop innovative drugs through our ongoing R&D efforts and advanced technologies, enhancing our competitiveness in both domestic and global markets," said Park Jae-hyun, CEO of Hanmi Pharmaceutical.
With the anticipated launch of Amoxatant Plus L in 2025, Hanmi Pharmaceutical is poised to further strengthen its position in the global hypertension market and set a new standard for hypertension treatment.
[Copyright (c) Global Economic Times. All Rights Reserved.]
